BHC Stock - Bausch Health Companies Inc.
Unlock GoAI Insights for BHC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.63B | $8.76B | $8.12B | $8.43B | $8.03B |
| Gross Profit | $6.84B | $6.20B | $5.76B | $6.04B | $5.78B |
| Gross Margin | 71.1% | 70.8% | 70.9% | 71.6% | 72.0% |
| Operating Income | $1.55B | $963.00M | $454.00M | $450.00M | $676.00M |
| Net Income | $-46,000,000 | $-592,000,000 | $-225,000,000 | $-948,000,000 | $-559,000,000 |
| Net Margin | -0.5% | -6.8% | -2.8% | -11.2% | -7.0% |
| EPS | $-0.13 | $-1.62 | $-0.59 | $-2.61 | $-1.57 |
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Visit WebsiteEarnings History & Surprises
BHCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | $1.23 | — | — | — |
Q4 2025 | Oct 29, 2025 | $1.07 | $1.16 | +8.4% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $0.97 | $0.90 | -7.2% | ✗ MISS |
Q2 2025 | Apr 30, 2025 | $0.83 | $0.59 | -28.9% | ✗ MISS |
Q1 2025 | Feb 19, 2025 | $1.65 | $1.15 | -30.3% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $1.03 | $1.12 | +8.7% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $0.88 | $0.89 | +1.1% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $0.75 | $0.59 | -21.3% | ✗ MISS |
Q1 2024 | Feb 22, 2024 | $1.01 | $1.15 | +13.9% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $0.92 | $1.03 | +12.0% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $0.75 | $0.81 | +8.0% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $0.75 | $0.52 | -30.7% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $0.92 | $1.02 | +10.9% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $0.92 | $0.76 | -17.4% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $0.89 | $0.55 | -38.2% | ✗ MISS |
Q2 2022 | May 10, 2022 | $1.03 | $0.72 | -30.1% | ✗ MISS |
Q1 2022 | Feb 23, 2022 | $1.08 | $1.27 | +17.6% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $1.07 | $1.14 | +6.5% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $0.97 | $0.98 | +1.0% | ✓ BEAT |
Latest News
Frequently Asked Questions about BHC
What is BHC's current stock price?
What is the analyst price target for BHC?
What sector is Bausch Health Companies Inc. in?
What is BHC's market cap?
Does BHC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BHC for comparison